Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Compass Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Compass Therapeutics, Inc.’s stock price such as:

• Compass Therapeutics, Inc.’s current stock price and volume
• Why Compass Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CMPX from analysts
• CMPX’s stock price momentum as measured by its relative strength

About Compass Therapeutics, Inc. (CMPX)

Before we jump into Compass Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Want to learn more about Compass Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Compass Therapeutics, Inc..

Compass Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Compass Therapeutics, Inc.’s stock price was $1.910.

Compass Therapeutics, Inc. is down 1.55% from its previous closing price of $1.940.

During the last market session, Compass Therapeutics, Inc.’s stock traded between $1.860 and $1.960. Currently, there are approximately 186.40 million shares outstanding for Compass Therapeutics, Inc..

Compass Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Compass Therapeutics, Inc. Stock Price History

Compass Therapeutics, Inc.’s (CMPX) price is currently down 12.79% so far this month.

During the month of July, Compass Therapeutics, Inc.’s stock price has reached a high of $2.360 and a low of $1.860.

Over the last year, Compass Therapeutics, Inc. has hit prices as high as $6.880 and as low as $1.610. Year to date, Compass Therapeutics, Inc.’s stock is down 64.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Compass Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Compass Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Compass Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Compass Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Compass Therapeutics, Inc. (CMPX) by visiting AAII Stock Evaluator.

Relative Price Strength of Compass Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Compass Therapeutics, Inc. has a weighted four-quarter relative price strength of 0.54%, which translates to a Momentum Score of 55 and is considered to be Average.

Want to learn more about how Compass Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Compass Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Compass Therapeutics, Inc.’s stock price is $1.910, which is down 1.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Compass Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.